Altre lingue Keymed Biosciences Inc.

Azioni

2162

KYG5252B1023

Mercato chiuso - Hong Kong S.E. Altri mercati azionari 10:08:35 19/04/2024			Variaz. 5gg	Var. 1 gen.
27,45 ^HKD	-7,42%		-15,54%	-44,09%

12/04	Keymed Biosciences avanza il farmaco per i tumori solidi con il primo studio su un paziente	MT
27/03	La perdita attribuibile di KeyMed Biosciences si allarga nel 2023	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Keymed Biosciences Advances Solid Tumors Drug With First Patient Study	12/04
KeyMed Biosciences’ Attributable Loss Widens in 2023	27/03
Keymed Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Keymed Biosciences Buys Back Shares	22/01
Keymed's Rhinosinusitis Treatment Achieves Primary Endpoints; Shares Rise 5%	27/12
Keymed Biosciences Inc. Announces Phase III Clinical Trial of Cm310 for the Treatment of Chronic Rhinosinusitis with Nasal Polyps	27/12
China Accepts New Drug Application for Keymed Biosciences' Atopic Dermatitis Injection; Shares Rise 4%	07/12
Keymed Biosciences Inc. Announces New Drug Application of Stapokibart Injection	07/12
Keymed Presents Phase 1 Trial Data for Gastric/Gastroesophageal Cancer Drug	08/11
Keymed Biosciences Inc. Announces the Latest Data from a Phase I Clinical Study of CMG901	08/11
Keymed Biosciences Inc. Announces CM310 Phase III Clinical Trial Topline Data Accepted for Poster Presentation at the European Academy of Dermatology and Venereology Congress 2023	11/10/23
Keymed Biosciences’ Profit Surges in H1	25/08/23
Keymed Biosciences Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	24/08/23
Keymed Biosciences to Acquire 18.7% of Kangnuo Xing for 150.6 Million Yuan	27/06/23
Keymed Presents Data on Phase 1 Study for Lymphoma, Myeloma Drug; Shares Fall 4%	12/06/23
Keymed Biosciences Inc. Announces Latest Data from the Phase I Clinical Study of CM313	12/06/23
Keymed Biosciences Completes Data Unblinding for Phase 3 Study of Eczema Treatment; Shares Rise 8%	30/05/23
Keymed Biosciences Inc. Announces Latest Development on Phase III Clinical Trial of CM310 for the Treatment of Moderate to Severe Atopic Dermatitis in Adults	30/05/23
Keymed Biosciences Inc. Announces Board and Committee Changes	17/04/23
License agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate, completed	30/03/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Keymed Biosciences Inc.

Azioni

2162

KYG5252B1023

Altre lingue

Filtri